One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
Steven P WolfVasiliki AnastasopoulouKimberley DrouschMarkus I DiehlBoris EngelsPoh Yin YewKazuma KiyotaniYusuke NakamuraKarin SchreiberHans SchreiberMatthias LeisegangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Two cancer-specific TCRs can be essential and sufficient to eradicate heterogeneous solid tumors expressing unmanipulated, autochthonous targets. We demonstrate that simplifications to adoptive TCR-therapy are possible without compromising efficacy.